Exploring the Evolving Treatment Landscape for Advanced Hepatocellular Carcinoma
Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.
Andrew X. Zhu, MD, PhD, professor of medicine at the Harvard Medical School and director of Liver Cancer Research at the Massachusetts General Hospital Cancer Center, discusses the evolving treatment landscape for patients with hepatocellular carcinoma (HCC).
For patients with advanced HCC, sorafenib (Nexavar) dominated the field for many years, according to Zhu. The multi-targeted tyrosine kinase inhibitor (TKI) lenvatinib (Lenvima) later joined the field as an alternative single-agent treatment option for patients with advanced HCC. This provided a second option for the frontline setting, and for a long time, clinical trials were unable to demonstrate better activity with other agents or regimens than single-agent sorafenib.
The combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) was able to demonstrate superiority compared with sorafenib in terms of overall survival more recently, and the combination received approval in May 2020.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
